301 related articles for article (PubMed ID: 20691151)
41. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
42. A thermosensitive liposome prepared with a Cu²⁺ gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy.
Tagami T; May JP; Ernsting MJ; Li SD
J Control Release; 2012 Jul; 161(1):142-9. PubMed ID: 22504351
[TBL] [Abstract][Full Text] [Related]
43. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved.
Lentacker I; Geers B; Demeester J; De Smedt SC; Sanders NN
Mol Ther; 2010 Jan; 18(1):101-8. PubMed ID: 19623162
[TBL] [Abstract][Full Text] [Related]
44. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
45. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
46. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin.
García MC; Calderón-Montaño JM; Rueda M; Longhi M; Rabasco AM; López-Lázaro M; Prieto-Dapena F; González-Rodríguez ML
Int J Pharm; 2022 May; 619():121691. PubMed ID: 35331830
[TBL] [Abstract][Full Text] [Related]
47. Lipoplex-Mediated Deintercalation of Doxorubicin from Calf Thymus DNA-Doxorubicin Complex.
Das A; Adhikari C; Chakraborty A
Langmuir; 2016 Sep; 32(35):8889-99. PubMed ID: 27465781
[TBL] [Abstract][Full Text] [Related]
48. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
49. Strategies to release doxorubicin from doxorubicin delivery vehicles.
Li J; Zhang B; Yue C; Wu J; Zhao L; Sun D; Wang R
J Drug Target; 2018 Jan; 26(1):9-26. PubMed ID: 28805085
[TBL] [Abstract][Full Text] [Related]
50. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
51. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
Yang B
Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
[TBL] [Abstract][Full Text] [Related]
52. SERS-active liposome@Ag/Au nanocomposite for NIR light-driven drug release.
Zhao Y; Zhao J; Shan G; Yan D; Chen Y; Liu Y
Colloids Surf B Biointerfaces; 2017 Jun; 154():150-159. PubMed ID: 28334692
[TBL] [Abstract][Full Text] [Related]
53. Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine.
Chen J; Yan GJ; Hu RR; Gu QW; Chen ML; Gu W; Chen ZP; Cai BC
Int J Nanomedicine; 2012; 7():3567-77. PubMed ID: 22904620
[TBL] [Abstract][Full Text] [Related]
54. Physicochemical Analysis of DPPC and Photopolymerizable Liposomal Binary Mixture for Spatiotemporal Drug Release.
Kenaan A; Cheng J; Qi D; Chen D; Cui D; Song J
Anal Chem; 2018 Aug; 90(15):9487-9494. PubMed ID: 30009597
[TBL] [Abstract][Full Text] [Related]
55. Doxorubicin loaded tumor-triggered targeting ammonium bicarbonate liposomes for tumor-specific drug delivery.
Cheng Y; Zou T; Dai M; He XY; Peng N; Wu K; Wang XQ; Liao CY; Liu Y
Colloids Surf B Biointerfaces; 2019 Jun; 178():263-268. PubMed ID: 30877911
[TBL] [Abstract][Full Text] [Related]
56. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
57. Ultrasound sensitive eLiposomes containing doxorubicin for drug targeting therapy.
Lin CY; Javadi M; Belnap DM; Barrow JR; Pitt WG
Nanomedicine; 2014 Jan; 10(1):67-76. PubMed ID: 23845926
[TBL] [Abstract][Full Text] [Related]
58. Focused ultrasound influence on calcein-loaded thermosensitive stealth liposomes.
Novell A; Al Sabbagh C; Escoffre JM; Gaillard C; Tsapis N; Fattal E; Bouakaz A
Int J Hyperthermia; 2015 Jun; 31(4):349-58. PubMed ID: 25677841
[TBL] [Abstract][Full Text] [Related]
59. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
[TBL] [Abstract][Full Text] [Related]
60. [Preparation and evaluation of doxorubicin hydrochloride liposomes modified by poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate].
Zhang D; Li JY; Wang XC; Yue HX; Hu MN; Yu X; Xu H
Yao Xue Xue Bao; 2015 Sep; 50(9):1174-9. PubMed ID: 26757556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
